Dive Brief:

摘要：

LaNova Medicines, a cancer drugmaker that previously licensed medicines to Merck & Co. and AstraZeneca, has agreed to be acquired by Sino BioPharmaceutical in a deal worth up to $950.9 million.

此前曾向默克公司和阿斯利康授权药物的抗癌药制造商LaNova Medicines已同意被中国生物制药以高达9.509亿美元的交易收购。

In an

在

agreement disclosed Tuesday

周二披露的协议

, Sino BioPharm will buy the approximately 95% of LaNova it doesn’t already own. Accounting for LaNova’s cash holdings, the net payment made by Sino Biopharm will total about $500 million.

中国生物制药将收购拉诺瓦约95%的股份（它尚未拥有的）。考虑到拉诺瓦的现金持有量，中国生物制药的净支付总额将约为5亿美元。

Once the deal is complete, LaNova will become a wholly owned subsidiary of

一旦交易完成，LaNova 将成为全资子公司。

Sino Biopharm

中国生物制药

, which previously invested in LaNova’s Series C1 financing that was

，之前曾参与LaNova的C1轮融资，该轮融资

announced last October

去年十月宣布的

.

。

Dive Insight:

潜水洞察：

LaNova was founded in Shanghai a little less than six years ago. In the time since, it has built a pipeline that includes eight clinical-stage compounds, including two licensed by

兰诺瓦于近六年前在上海成立。此后，它已建立了一条包括八个临床阶段化合物的管道，其中两个已获得许可。

AstraZeneca

阿斯利康

and

和

Merck & Co.

默克公司

in 2023 and 2024 deals, respectively.

分别在2023年和2024年达成协议。

The company’s emergence parallels the

公司的发展历程与之平行。

rapid gains made by China’s biotech sector

中国生物技术领域取得的快速进展

, which in the span of a decade has gone from a copycat factory to an innovative hub that regularly designs drugs attractive to multinational pharmaceutical firms in the U.S. and Europe.

，这家公司在十年的时间里，从一个模仿者工厂发展成为了一个创新中心，定期设计出对美国和欧洲跨国制药公司具有吸引力的药物。

AstraZeneca’s deal involved an antibody-drug conjugate, or ADC, that LaNova designed to bind GPRC5D, a protein target rising on the radar screens of companies

阿斯利康的交易涉及一种抗体-药物偶联物（ADC），这是LaNova设计用来结合GPRC5D的，GPRC5D是一种在公司雷达上日益受到关注的蛋白质靶标。

developing medicines for multiple myeloma

开发多发性骨髓瘤药物

. That pact handed LaNova $55 million upfront.

.该协议使LaNova获得了5500万美元的预付款。

Then, last November, Merck

然后，去年十一月，默克公司

bought rights to LaNova’s LM-299

购买了LaNova的LM-299权利

, a bispecific antibody aimed at the cancer drug targets PD-1 and VEGF. This

，一种针对癌症药物靶点PD-1和VEGF的双特异性抗体。这个

kind of antibody is newly of interest

某种抗体是新近引起兴趣的

after the success of ivonescimab, a similarly structured drug that outperformed Merck’s dominant immunotherapy in a

在伊沃内西单抗取得成功之后，这种结构相似的药物在一项试验中表现优于默克公司主导的免疫疗法。

head-to-head lung cancer study

头对头肺癌研究

. Merck paid LaNova $588 million in upfront cash to license LM-299.

默克公司向LaNova支付了5.88亿美元的预付现金，以获取LM-299的许可。

Beyond those two medicines, LaNova is also testing an antibody targeting the protein CCR8 for use in gastric cancer and other solid tumors, as well as an ADC aimed at Claudin 18.2. The latter drug is in Phase 3 trials in China, while the former is in Phase 2.

除了这两种药物，拉诺瓦还在测试一种针对蛋白质CCR8的抗体，用于胃癌和其他实体肿瘤，以及一种针对Claudin 18.2的抗体药物偶联物（ADC）。后一种药物在中国处于第三期试验阶段，而前一种药物则处于第二期试验阶段。